- HMS Community Values
- Introduction to Clinical Research Training
- Medical Education
- Dean for Medical Education
- Financial Aid
- Student Services
- Office of Student Affairs
- Academic Societies at HMS
- Walter Bradford Cannon Society
- William Bosworth Castle Society
- Irving M. London Society (HST)
- Oliver Wendell Holmes Society
- Francis Weld Peabody Society
- Scholars in Medicine (SIM)
- Multicultural Affairs
- A View of Student Life
- Career Advising - Roadmap to Residency
- MD Programs
- Student Handbook
- Education Matters
- Student Profiles
- Curriculum Services
- The Academy at Harvard Medical School
- Program Evaluation and Student Assessment
- Anatomical Gift Program
- Teaching Awards
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- The Academy
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Harvard Medical School Event Calendar
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- Cancer Biology & Therapeutics Program
- Celiac Program
- Department of Medicine
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Big Data In Healthcare
- Institutional Planning and Policy
- Master of Medical Sciences In Clinical Investigation
- Office of Global Education
- Portugal Clinical Scholars Research Training Program
- Safety Quality Informatics and Leadership
- South American Clinical Research Training Program | SACRT
- Shenzhen-HMS Initiative in International Education
- test page
- HMS Foundation Funds
- Contact @HMS
- Office of Global Education
- Human Resources
- Jobs @ HMS
- Dental Medicine
- Harvard University
- Contact us
Aspirin and Cancer Risk
The regular use of aspirin significantly reduces the overall risk of cancer, according to an analysis led by Harvard Medical School researchers at Massachusetts General Hospital. Their review of data from two major, long-term epidemiologic studies also showed that the reduction primarily reflects a lower risk of colorectal cancer and other tumors of the gastrointestinal tract.
The findings, published in JAMA Oncology, suggest that the use of aspirin may complement, but not replace, the preventive benefits of colonoscopy and other methods of cancer screening.
“We now can recommend that many individuals consider taking aspirin to reduce their risk of colorectal cancer—particularly those with other reasons for regular aspirin use, such as heart disease prevention—but we are not at a point where we can make a general recommendation for overall cancer prevention,” said Andrew Chan, HMS associate professor of medicine at Mass General and senior author of the report.
“Our findings imply that aspirin use would be expected to prevent a significant number of colorectal cancers above and beyond those that would be prevented by screening,” Chan said. “It may have even greater benefit in settings in which the resources to devote to cancer screening are lacking,”
A large number of studies have supported regular aspirin use to prevent colorectal cancer, but aspirin’s effects on overall cancer risk have not been clear. To investigate that question, the research team analyzed data spanning 32 years from almost 136,000 participants in the Nurses’ Health Study and the Health Professionals Follow-up Study.
The scientists found that participants who reported regular aspirin use—taking either a standard or a low-dose aspirin tablet at least twice a week—had a 3 percent absolute lower risk of any type of cancer compared to those not reporting regular aspirin use. Regular aspirin use reduced the risk of colorectal cancer by 19 percent and the risk of any gastrointestinal cancer by 15 percent.
No reduction was seen in the risk of breast, prostate or lung cancer.
“At this point, it would be very reasonable for individuals to discuss with their physicians the advisability of taking aspirin to prevent gastrointestinal cancer, particularly if they have risk factors such as a family history.” —Andrew Chan
Aspirin’s protective benefit appeared after five years of continuous use at dosages ranging from 0.5 to 1.5 standard tablets a week or one low-dose tablet a day. The researchers estimate that regular aspirin use could prevent close to 30,000 gastrointestinal tract tumors in the U.S. each year. It could also prevent an additional 7,500 colorectal tumors among U.S. adults over 50 who have endoscopic screening and 9,800 among the almost 30 million who are not screened, they said.
The benefit related to other gastrointestinal tumors appeared after six years and at the same dosage level—equivalent to a daily low-dose tablet—that many people take to prevent cardiovascular disease.
“At this point, it would be very reasonable for individuals to discuss with their physicians the advisability of taking aspirin to prevent gastrointestinal cancer, particularly if they have risk factors such as a family history,” said Chan.
“But this should be done with the caveat that patients be well informed about the potential side effects of regular aspirin treatment and continue their regular screening tests.” Chan said. “Furthermore, aspirin should not be viewed as a substitute for colonoscopy or other cancer screening tests.”
The research team also included authors from Dana-Farber Cancer Institute and the Harvard T.H. Chan School of Public Health.
The study was supported by a large number of National Institutes of Health grants.
Adapted from a Mass General news release.
Stay informed via email on the latest news, research, and
media from Harvard Medical School.